RheumNow Live starts this Saturday! Are you registered yet? https://t.co/x3JJP8uZR4 What session are you most looking forward to? https://t.co/rP54RLUYw2

COVID-19 mRNA Vaccine Safety #s - From ~300 million doses, there were 340,522 VAERS reported side effects, 92% mild, 6·6% serious (non-death)& 1·3% deaths(none from Anaphylaxis-0.025%). From 7.9 million V-safe participants, 1/2 had some AE. https://t.co/LV3aiOBOah https://t.co/mbYkZeywEo

Study of 338 psoriatic pts assessed carotid total plaque area (TPA) and cardiac troponin I (cTnI) & NT-proBNP. TPA was associated with troponin 1 (β coefficient 0.52) and NT-proBNP (β coefficient 0.24); both p<0.001. https://t.co/NXUBByAD37 https://t.co/ZQMFiqTzDF

Retrospective cohort study of 338 pregnancies in IMID pts (~1/2 w/ IBD); 23% w/ biologic exposure had increase in post-partum flares (OR 3.44) & less being breastfeed (OR 0.44). Maternal and neonatal pregnancy outcomes were similar https://t.co/8pu2p8tK0s https://t.co/bVQx9La5j3

Korean study (TB endemic area) shows the risk of mTB & nontuberculous mycobact infx (NTM) are equal and nearly doubled in RA pts on TNFi. Among 4356 RA (1089 on TNFi) NTM & TB rates were 328- and 341/100K PY (US rate is 6/100K PY) https://t.co/QwzTYt3wX4 https://t.co/GLWreoQ6ih

ICYMI: CDC reports no cross-reactivity of serologic tests performance between Dengue, Zika and SARS-CoV-2 EIA. Study of febrile patients in Puerto Rico (DENV is endemic) with confirmed SARS-CoV-2, DENV, or Zika Dx. EIA specificity was ≥98% https://t.co/jM8UKwBp7u https://t.co/fOc8Ay8KU3

RheumNow Live is Coming to Town! Have you signed up for RheumNow Live yet? We still have space available. https://t.co/FBCQRu32gO https://t.co/KoGR8An6af https://t.co/qtwPbMzqSO

ICYMI: anti-IL-23 therapy is not effective in Axial Spondyloarthritis. While ustekinumab, guselkumab and risankizumab are approved in psoriasis (& PsA for GUS, RIZ), studies of Ustekinumab and risankizumab failed to show efficacy in axSpA https://t.co/6MQ3CMU7YG https://t.co/okl2e1Q6Hs

ICYMI: Kawasaki Disease Guideline from ACR and Vasculitis Foundation https://t.co/ixKL6juqkM https://t.co/Nw4yi0OZPy

ICYMI: Good review of Diagnosis and Treatment of Pulmonary Sarcoidosis in JAMA. - Lung progression (in only 10%) assoc w/ 12-18% 5yr mortality - Sx Sarcoid w/ Lung: start Pred 20 to 40 mg/d for 2 -6 wks - Steroid sparing w/ MTX, AZA or TNFi https://t.co/Ue4V1uAhRF https://t.co/5ap3bPzoNk

ICYMI: Undifferentiated Arthritis Does Not Follow an RA Course UA is common in medical practice and many advocate early use of DMARDs; yet a recent study shows that despite DMARD use, UA patients do not fair well with this approach. https://t.co/l0U4IVAXMG https://t.co/8YPM8DgX8H

ICYMI: COMPLETE-PsA Trial studied MTX vs MTX + leflunomide in 78 active untreated PsA pts. MTX+LEF was superior to MTX alone at wk 16 (PASDAS 3·1 vs 3·7; p=0·025). Combo group had more N/V (44% v 28%), ^ALT (31% vs 18%). https://t.co/tg5eETiMO4 https://t.co/bC45AAnP3h